Autologous Immune Enhancement Therapy in a Case of Gall Bladder Cancer Stage IV After Surgical Resection and Chemotherapy Yielding a Stable Non-Progressive Disease

J Cancer Res Ther. Jul-Sep 2014;10(3):752-4. doi: 10.4103/0973-1482.136048.

Abstract

Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer
  • Combined Modality Therapy
  • Female
  • Gallbladder Neoplasms / diagnosis
  • Gallbladder Neoplasms / immunology
  • Gallbladder Neoplasms / pathology*
  • Gallbladder Neoplasms / therapy*
  • Humans
  • Immunotherapy*
  • Killer Cells, Natural / immunology
  • Middle Aged
  • T-Lymphocytes / immunology
  • Treatment Outcome